Literature DB >> 8857712

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited.

J L Cummings1, D Kaufer.   

Abstract

Altered cholinergic function is a prominent feature of AD. The neuropsychological impairments of AD are attributed, at least partially, to the cholinergic disturbance, and current approaches to treatment of the cognitive abnormalities attempt to enhance cholinergic function. Behavioral changes are common in AD and include psychosis, agitation, depression, anxiety, personality alterations, and neurovegetative changes. The contribution of the cholinergic deficiency to the behavioral alterations has been little explored, but neurochemical, neuroanatomic, pharmacologic, and clinical observations suggest that the cholinergic deficiency contributes importantly to the neuropsychiatric dimension of AD. Investigation of the role of cholinergic dysfunction in the behavioral changes of AD will improve understanding of the pathophysiologic basis of these abnormalities and may lead to new types of therapy for the neuropsychiatric disturbances associated with this common dementing disorder.

Entities:  

Mesh:

Year:  1996        PMID: 8857712     DOI: 10.1212/wnl.47.4.876

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

Review 1.  Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.

Authors:  D I Kaufer
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy.

Authors:  Charles F Reynolds; Meryl A Butters; Oscar Lopez; Bruce G Pollock; Mary Amanda Dew; Benoit H Mulsant; Eric J Lenze; Margo Holm; Joan C Rogers; Sati Mazumdar; Patricia R Houck; Amy Begley; Stewart Anderson; Jordan F Karp; Mark D Miller; Ellen M Whyte; Jacqueline Stack; Ariel Gildengers; Katalin Szanto; Salem Bensasi; Daniel I Kaufer; M Ilyas Kamboh; Steven T DeKosky
Journal:  Arch Gen Psychiatry       Date:  2011-01

3.  Nerve growth factor (NGF) augments cortical and hippocampal cholinergic functioning after p75NGF receptor-mediated deafferentation but impairs inhibitory avoidance and induces fear-related behaviors.

Authors:  J Winkler; G A Ramirez; L J Thal; J J Waite
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

4.  Neuroprotection in Alzheimer's disease - new strategies for treatment.

Authors:  A Nordberg
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 6.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

7.  Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach.

Authors:  Rochelle E Tractenberg; Myron F Weiner; Jeffrey L Cummings; Marian B Patterson; Leon J Thal
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2005       Impact factor: 2.198

8.  Neuropathological changes in the nucleus basalis in schizophrenia.

Authors:  M R Williams; R Marsh; C D Macdonald; J Jain; R K B Pearce; S R Hirsch; O Ansorge; S M Gentleman; M Maier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-12-11       Impact factor: 5.270

9.  An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients.

Authors:  Ellen M Whyte; Eric J Lenze; Meryl Butters; Elizabeth Skidmore; Kris Koenig; Mary Amanda Dew; Louis Penrod; Benoit H Mulsant; Bruce G Pollock; Leonard Cabacungan; Charles F Reynolds; Michael C Munin
Journal:  Cerebrovasc Dis       Date:  2008-07-31       Impact factor: 2.762

10.  Current therapeutic options for Alzheimer's disease.

Authors:  Alberto Lleó
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.